Bayer: Science For A Better Life

United States of America

Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Intended Audience: Pulmonary Hypertension Specialists, Pulmonologists, Cardiologists, Internal Medicine

Bayer TA Rationale for Educational Support:

  • Riociguat, pulmonary thromboendarterectomy (PTE), or Balloon pulmonary angioplasty (BPA), alone or in combination, for CTEPH (evidence based and current clinical practice)
  • Awareness of COVID-19 related VTE/PE and long term complications, specifically CTEPH
  • Understanding the need for early screening and diagnosis of CTEPH in patients who have had VTE (pulmonary embolism and/or deep vein thrombosis
  • Understanding the progression and evolution from venous thromboembolism (VTE) to CTED/CTEPH

Proposal Requirements:

The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).

The proposal should include:

  • Needs assessment
  • Educational design and rationale for selection (where applicable)
  • Learning Objectives
  • Proposed Faculty
  • Participant recruitment plan (where applicable)
  • Outcomes strategy/plan
  • Detailed budget

Provider Justification:

Copy of most recent accreditation letter and status

Process

Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.

Acceptance of a Bayer educational grant indicates that you will:

  • Reconcile grant funding within 60 days of completion of the educational program
  • Permit a Bayer Medical Affairs representative to audit live programs
  • Share activity data and outcomes metrics within 30 days of their availability

References:

  1. Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J. 2009;33:325-31.
  2. Bonderman D, Skoro-Sajer N, Jakowitsch J, et al. Predictors of outcome in chronic thromboembolic pulmonary hypertension. Circulation. 2007;115:2153-2158.
  3. Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med. 2008;177:1122-1127.
  4. Ghofrani HA, Hoeper MM, Hoeffken G, et al. Riociguat dose titration in patients with chronic thromboembolic pulmonary hypertension or pulmonary arterial hypertension. Am J Respir Crit Care Med. 2009;179:A3337.
  5. Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation. 2009;120:1248-1254.
  6. Kim NJ. Riociguat: an upcoming therapy in chronic thromboembolic pulmonary hypertension? Eur Respir Rev. 2010;19:68-71.
  7. Sugura T, Tanabe N, Saito M, et al. Effects of underlying disease in CTEPH patients with regard to onset and prognosis. Am J Respir Crit Care Med. 2010;181:A1592.